|
JPS5875614A
(ja)
*
|
1981-10-28 |
1983-05-07 |
Matsushita Electric Ind Co Ltd |
焼却炉の排ガス浄化装置
|
|
DE4312016A1
(de)
*
|
1993-04-13 |
1994-10-20 |
Goedecke Ag |
Stabile Ketamin-Lösungen
|
|
DE19619665C2
(de)
*
|
1996-05-15 |
2001-03-08 |
Goedecke Ag |
Racemattrennung von Ketamin
|
|
BRPI0002693B8
(pt)
*
|
2000-06-19 |
2021-05-25 |
Cristalia Produtos Quim Farmaceuticos Ltda |
processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
US9072662B2
(en)
|
2004-03-29 |
2015-07-07 |
Auris Medical Ag |
Methods for the treatment of tinnitus induced by cochlear excitotoxicity
|
|
US20060063802A1
(en)
|
2004-03-29 |
2006-03-23 |
Matthieu Guitton |
Methods for the treatment of tinnitus induced by cochlear excitotoxicity
|
|
US8268866B2
(en)
|
2004-03-29 |
2012-09-18 |
Matthieu Guitton |
Methods for the treatment of tinnitus induced by cochlear excitotoxicity
|
|
PT1928405E
(pt)
|
2005-09-28 |
2014-10-20 |
Auris Medical Ag |
Composições farmacêuticas para o tratamento de distúrbios do ouvido interno
|
|
WO2013087090A1
(en)
|
2011-12-12 |
2013-06-20 |
Auris Medical Ag |
Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
|
|
US20140275278A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
HRP20211629T1
(hr)
|
2013-09-13 |
2022-02-04 |
National University Corporation Chiba University |
Primjena r-ketamina i njegove soli kao lijekova
|
|
EP3179993B1
(de)
|
2014-08-13 |
2021-01-20 |
Janssen Pharmaceutica NV |
Esketamine zur verwendung in einem verfahren zur behandlung von depression
|
|
CA2961208A1
(en)
|
2014-09-15 |
2016-03-24 |
Janssen Pharmaceutica Nv |
Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
US20160332962A1
(en)
*
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
US20200009081A1
(en)
|
2017-09-13 |
2020-01-09 |
Janssen Pharmaceutica N.V. |
Delivery Of Esketamine For The Treatment Of Depression
|
|
MX2020006650A
(es)
|
2017-12-22 |
2020-11-06 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
CN118453559A
(zh)
|
2018-02-15 |
2024-08-09 |
国立大学法人千叶大学 |
炎症性疾病或骨病的预防或治疗剂及医药组合物
|
|
CN110218157B
(zh)
*
|
2018-03-01 |
2022-08-23 |
江苏恒瑞医药股份有限公司 |
一种r-氯胺酮及其可药用盐的制备方法
|
|
CA3099293A1
(en)
|
2018-05-04 |
2019-11-07 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
BR112020023882A2
(pt)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
método para tratar transtorno depressivo maior
|
|
WO2020070547A1
(en)
|
2018-10-05 |
2020-04-09 |
Clexio Biosciences Ltd. |
Dosage regime of esketamine for treating major depressive disorder
|
|
US11865088B2
(en)
|
2018-10-05 |
2024-01-09 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
EP3863617A1
(de)
|
2018-10-11 |
2021-08-18 |
Clexio Biosciences Ltd. |
Esketamin zur verwendung bei der behandlung einer schweren depressiven störung
|
|
WO2020178653A1
(en)
|
2019-03-05 |
2020-09-10 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
WO2021137148A1
(en)
|
2019-12-30 |
2021-07-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
US12268658B2
(en)
|
2019-12-30 |
2025-04-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
CN112125816A
(zh)
*
|
2020-03-17 |
2020-12-25 |
国药集团工业有限公司 |
一种氯胺酮、其衍生物或其盐的消旋化方法
|
|
WO2025057111A1
(en)
|
2023-09-12 |
2025-03-20 |
Clexio Biosciences Ltd. |
Esketamine or a pharmaceutical salt thereof for use in a method of treating major depressive disorder
|